Japan Tissue Engineering Co., Ltd. (JP:7774) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Japan Tissue Engineering Co., Ltd. has announced the National Health Insurance listing of its innovative treatment for vitiligo, ‘JACEMIN’, starting October 1, 2024. ‘JACEMIN’ is a regenerative medical product that transplants autologous cultured epidermis, maintaining melanocytes to restore pigmentation in patients. This low-invasive treatment is expected to significantly improve the quality of life for vitiligo patients in Japan.
For further insights into JP:7774 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money